Pharmafile Logo

MAKING THE FIRST YEAR MATTER

October 26, 2021 |  

*Mind+Matter closes its first year of business celebrating more than £4 million of new business wins in the UK *The global agency launched in Jan 21 has also been awarded a ‘Communique’ award for ‘Excelling in multi-channel campaigns’ for its work with CSL Behring, alongside six further award commendations and wins  *The agency offers a ‘health first, sector second’ approach with access to sector experts with unparalleled breadth and depth of capabilities *The growth has led to more than 60 new hires globally, and senior promotions to the UK leadership team alongside the launch of Gravity.ai – a first of its kind global healthcare intelligence data platform

Mind+Matter(an Ashfield Health company, part of UDG Healthcare), a ‘global creative powerhouse in health’ is celebrating its first year of business after securing more than £4 million in new business revenue across key strategic wins that span pharma, medical devices, consumer and animal health clients.

Since the launch of its new proposition in January 2021 following the merger of Pegasus, Ashfield Digital and Creative and Cambridge Biomarketing, the UK Mind+Matter team, led by Corrina Safeio, has gone from strength to strength, drawing on the expertise of its world-class experts based globally.

New senior roles include the promotion of Ian Rayfrom Associate Creative Director to Creative Director, and Kesha Tansey to Client Director. Ian and Kesha join the UK Mind+Matter leadership team and will pay a key role in shaping the future strategy and direction of the agency.

Safeio says it’s already very clear by the raft of new business wins that the health sector needs a deeply interconnected, cross-sector response to both existing clients and new client challenges.

“It’s been a phenomenal first year for Mind+Matter and I’m extremely proud of our talented team and what we have been able to accomplish together. Creating meaningful experiences by bringing data and emotion together to drive behaviour change is at the heart of what we do, day in day out. It’s this proposition alongside our health first, sector second approach that has chimed most with clients –existing and new.”

At the heart of the Mind+Matter offer is CHANGE, a behavioural science-led strategic methodology co-created with the internationally recognised Centre for Behaviour Change at University College London (itself an expert voice in the public health response to Covid-19).

In its first year, Mind+Matter also launched Gravity.ai a first of its kind global healthcare intelligence data platform. Gravity.ai incorporates artificial intelligence, predictive analytics, data modelling and scientific human consultancy to better understand audiences, behaviour and channel performance, ensuring clients get the best value for their investment.

Safeio adds: “Covid has shown how our individual health is also a truly global issue and personalised communications have never been more important. Matched with our deep earned, owned and paid expertise, Gravity.ai allows us to discover meaningful links between demographics, technologies, and customer behaviours and track the changing dynamics of HCP, patient and consumer communications in a rapidly shifting digital world. This powers our planning model CHANGE, along with proven behavioural science. It’s powerful stuff that delivers impactful, measurable results.”

Ben Beckley leads the new agency from Boston in the US, along with Managing Directors Corrina Safeio and Carina Whitridge, who head up the EMEA and US regions respectively.

This content was provided by Inizio

Company Details

 Latest Content from  Inizio 

How a hybrid approach delivered fast insights to feed into an oncology product’s adoption strategy

Our client wanted to quantify how ovarian cancer patients are managed prior to product launch, but also needed to understand why patients do or do not receive key diagnostic tests...

Oncology experience & expertise

Did you know 25% of our business is in Oncology?

First, we need to talk: mental healthcare in the MENA region

In our final installment of articles exploring mental health in emerging markets, we take an in-depth look at the situation in the MENA region

Atopic Dermatitis — Going Beyond the Pill

Published in Pharma Exec April 2018 by Mariel Metcalfe

ESOMAR Asia Pacific 2018

13-15 May, Bangkok

Eyeforpharma – Real World Evidence 2018

16-17 May in Tokyo, Japan

Intellus Worldwide Summit 2018

Visit us on stand number 413

How buyer insights supported the development of an effective market strategy

Our client was developing a new product for HIV and needed to understand buyer willingness to pay in the emerging markets of South Africa, Kenya, and India. They needed to...

Conducting market research for scientific publication guide

Conducting and using market research for publication can be valuable for shaping opinions in healthcare. The findings can be used to influence existing perceptions, change current practices and behaviour in...

Therapy Watch appoints new Associate Director

Research Partnership has appointed Mark Hollis to join the Therapy Watch team as Associate Director. Mark has 8 years’ experience in syndicated healthcare, and previously worked in the Market Prognosis team at IQVIA...